Since alanine aminotransferase (ALT) is commonly used to measure liver injury, ALT has been used as an endpoint marker in many NAFLD and nonalcoholic steatohepatitis (NASH) studies. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.